NASDAQ · CHEMICALS & ALLIED PRODUCTS · LARGE CAP
Innospec Inc. IOSP
17 fiscal years on record · USD · FY2025 reported · SEC filings only
12 YEARS OF DIVIDEND GROWTH
In brief
What this company does
Written from the business description in INNOSPEC INC.'s annual report to the U.S. Securities and Exchange Commission, filed 18 February 2026. Every sentence was checked against that document before publication.
Growth
USD 1.8B
Revenue, FY2025 · full 17-year series below
Revenue $B
Net income $B
FY2025 · Revenue 1.8 · Net income 0.1
Compound annual growth
−3.3%
+8.3%
+5.8%
+6.6%
−4.3%
+32.4%
−0.2%
−4.3%
+32.1%
−0.4%
+3.1%
+10.1%
+10.5%
+10.9%
+20.8%
+19.1%
+8.5%
+24.4%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +8.3% a year over five years — but profit grew faster: net income at +32.4%, earnings per share at +32.1%.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
7 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 7.3% · Net 6.6%
ROE
FY2025 · ROE 9.2%
Each USD of equity produced 9 cents of profit this year.
The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 1.8 | 1.8 | 1.9 | 2.0 | 1.5 | 1.2 | 1.5 | 1.5 | 1.3 | 0.9 | 1.0 | 1.0 | 0.8 | 0.8 | 0.8 | 0.7 | 0.6 |
| Operating income $B | 0.1 | 0.2 | 0.2 | 0.2 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 |
| EBITDA $B | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 |
| Free cash flow $B | · | · | · | · | · | · | · | · | · | · | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.1 |
| EPS, diluted $ | 4.67 | 1.42 | 5.56 | 5.32 | 3.75 | 1.16 | 4.54 | 3.45 | 2.52 | 3.33 | 4.86 | 3.38 | 3.22 | 2.81 | 1.92 | 2.97 | 0.26 |
| Dividend / sh $ | 1.71 | 1.55 | 1.41 | 1.28 | 1.16 | 1.04 | 1.02 | 0.89 | 0.77 | 0.67 | 0.61 | 0.55 | 0.50 | 2.00 | 0.00 | 0.00 | 0.05 |
| Payout % | 36 | 109 | 25 | 24 | 31 | 89 | 22 | 26 | 30 | 20 | 12 | 16 | 15 | 70 | 0 | 0 | 19 |
| ROE % | 9.2 | 3.0 | 12.7 | 12.8 | 9.4 | 3.1 | 12.9 | 10.5 | 8.5 | 12.9 | 21.3 | 18.2 | 21.4 | 20.3 | 14.6 | 32.2 | 4.1 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 83 reconciliationsAUDITED
Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityChemicals & Allied Products
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009